drugset / Trial / NCT00012467

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

NCT00012467

Phase 2 Completed 60 enrolled InterMune
Double-blindTreatment

Summary

The purpose of this study is to examine the antifungal activity of recombinant interferon-gamma 1b (rIFN-gamma 1b) given with standard antifungal therapy.

Timeline

Start
2000-01
Primary completion
Completion
2001-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon gamma-1b Protein / enzyme biologic Subcutaneous
Background Amphotericin B Unknown Intravenous
Background Fluconazole Small molecule Oral
Background Flucytosine Small molecule Oral
Background Itraconazole Small molecule Oral